Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Rea...
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
About this item
Full title
Author / Creator
Iwamoto, Hideki , Shimose, Shigeo , Noda, Yu , Shirono, Tomotake , Niizeki, Takashi , Nakano, Masahito , Okamura, Shusuke , Kamachi, Naoki , Suzuki, Hiroyuki , Sakai, Miwa , Kajiwara, Akira , Itano, Satoshi , Tanaka, Masatoshi , Yamaguchi, Taizo , Kuromatsu, Ryoko , Koga, Hironori , Torimura, Takuji and on behalf of The Kurume Liver Cancer Study Group of Japan
Publisher
Basel: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel: MDPI AG
Subjects
More information
Scope and Contents
Contents
Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC. Materials and Methods: This is a mu...
Alternative Titles
Full title
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Authors, Artists and Contributors
Author / Creator
Shimose, Shigeo
Noda, Yu
Shirono, Tomotake
Niizeki, Takashi
Nakano, Masahito
Okamura, Shusuke
Kamachi, Naoki
Suzuki, Hiroyuki
Sakai, Miwa
Kajiwara, Akira
Itano, Satoshi
Tanaka, Masatoshi
Yamaguchi, Taizo
Kuromatsu, Ryoko
Koga, Hironori
Torimura, Takuji
on behalf of The Kurume Liver Cancer Study Group of Japan
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8199943
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8199943
Other Identifiers
ISSN
2072-6694
E-ISSN
2072-6694
DOI
10.3390/cancers13112786
